Browsing by Author Lynch, Kevin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2007Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) GenotypeBalleine, Rosemary; Clarke, Christine; Gurney, Howard; Hoskins, Janelle; Mann, Graham; McLachlan, Andrew; Rivory, Laurent; Wilcken, Nicholas; Wong, Mark; Collins, Michael; Delforce, S-E; Lynch, Kevin; Schran, H.; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); School of Medical Sciences: Pharmacology; Western Clinical School: Westmead Millennium Institute; Pharmacy; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteImatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype, Clinical Pharmacology & Therapeutics, vol.82,(1),2007,pp 33-40
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2005Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.Joshua, A; Kefford, Richard (Rick); Millward, Michael; Aamdal, Steinar; Hersey, Peter; Lynch, Kevin; Thomson, Damien; Toner, Guy C.; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; MedicineMulti-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma., Investigational New Drugs, vol.23,(3),2005,pp 253-256